COVID-19 versus HIT hypercoagulability
Authors:
- Theodore E. WarkentinTWTheodore E. Warkentin
- Scott KaatzSKScott Kaatz
- 1 December 2020
- journal article
- review article
- Published by Elsevier in Thrombosis Research
- Vol. 196, 38-51
Abstract
No abstract availableKeywords
Funding Information
- Janssen Canada
- Bristol-Myers Squibb Canada
This publication has 117 references indexed in Scilit:
- Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HITBlood, 2011
- Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulationThrombosis and Haemostasis, 2011
- Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopeniaBlood, 2010
- Formation of anti–platelet factor 4/heparin antibodies after cardiac surgery: Influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen statusThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Drug-Induced Immune-Mediated Thrombocytopenia — From Purpura to ThrombosisNew England Journal of Medicine, 2007
- Gender imbalance and risk factor interactions in heparin-induced thrombocytopeniaBlood, 2006
- Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysisBlood, 2005
- Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systemsThrombosis and Haemostasis, 2004
- Delayed-Onset Heparin-Induced Thrombocytopenia and Cerebral Thrombosis after a Single Administration of Unfractionated HeparinNew England Journal of Medicine, 2003
- The detection of d-dimer in plasma by enzyme immunoassayBlood Coagulation & Fibrinolysis, 1994